Cancers (Nov 2023)

Radiomics and Clinicopathological Characteristics for Predicting Lymph Node Metastasis in Testicular Cancer

  • Catharina Silvia Lisson,
  • Sabitha Manoj,
  • Daniel Wolf,
  • Christoph Gerhard Lisson,
  • Stefan A. Schmidt,
  • Meinrad Beer,
  • Wolfgang Thaiss,
  • Christian Bolenz,
  • Friedemann Zengerling,
  • Michael Goetz

DOI
https://doi.org/10.3390/cancers15235630
Journal volume & issue
Vol. 15, no. 23
p. 5630

Abstract

Read online

Accurate prediction of lymph node metastasis (LNM) in patients with testicular cancer is highly relevant for treatment decision-making and prognostic evaluation. Our study aimed to develop and validate clinical radiomics models for individual preoperative prediction of LNM in patients with testicular cancer. We enrolled 91 patients with clinicopathologically confirmed early-stage testicular cancer, with disease confined to the testes. We included five significant clinical risk factors (age, preoperative serum tumour markers AFP and B-HCG, histotype and BMI) to build the clinical model. After segmenting 273 retroperitoneal lymph nodes, we then combined the clinical risk factors and lymph node radiomics features to establish combined predictive models using Random Forest (RF), Light Gradient Boosting Machine (LGBM), Support Vector Machine Classifier (SVC), and K-Nearest Neighbours (KNN). Model performance was assessed by the area under the receiver operating characteristic (ROC) curve (AUC). Finally, the decision curve analysis (DCA) was used to evaluate the clinical usefulness. The Random Forest combined clinical lymph node radiomics model with the highest AUC of 0.95 (±0.03 SD; 95% CI) was considered the candidate model with decision curve analysis, demonstrating its usefulness for preoperative prediction in the clinical setting. Our study has identified reliable and predictive machine learning techniques for predicting lymph node metastasis in early-stage testicular cancer. Identifying the most effective machine learning approaches for predictive analysis based on radiomics integrating clinical risk factors can expand the applicability of radiomics in precision oncology and cancer treatment.

Keywords